August 21, 2017
Oncologists and urologists who received payments from the pharmaceutical industry did not write a larger number of prescriptions for major prostate cancer drugs than those who did not, according to findings published in Cancer.
“Abiraterone and enzalutamide are the 2 most widely prescribed drugs for metastatic castration-resistant prostate cancer, with $2.2 billion and $1.
In the Journals
August 15, 2017
Patients with newly diagnosed cancer have elevated risk for MI and stroke, particularly in the first 6 months after diagnosis, according to data published in the…
In the Journals Plus
August 14, 2017
Older patients with cancer often reported having better physical function, mental health and social support than their caregivers’ assessments, according to study…
August 10, 2017
In this guest commentary,
Leonard J. Appleman, MD, PhD,
of the division of hematology/oncology at the University of Pittsburgh Medical Center Hillman…